Is now the moment when drug development, which for years has only gotten more di...
FogPharma CEO Mathai Mammen is taking the stage at #JPM24 Tuesday for what he’s ...
The economics of CRISPR don't currently work for very rare diseases. The Doudna ...
Health secretary Xavier Becerra, once ‘invisible,’ is finally making inroads wit...
AUR-101 is under clinical development by Aurigene Oncology and currently in Phas...
Subasumstat is under clinical development by Takeda Pharmaceutical and currently...
Approval for zolbetuximab was quashed after the FDA found deficiencies in the co...
The proceeds from the private placement will fund the development of Zealand’s o...
Set to lose Keytuda patent protection in 2028, MSD is shoring up its oncology po...
Biocytogen Pharmaceuticals and Radiance Biopharma have signed an exclusive optio...
BIOS Health has partnered with the City of Bakersfield, Kern County, and Kern Ve...
The EC has granted approval for Pfizer’s Talzenna (talazoparib) to treat adults ...
Johnson & Johnson (J&J) has signed a definitive agreement for the acquisition of...
HH-006 is under clinical development by Huahui Health and currently in Phase I f...
Today's Readout newsletter: Sky high deal expectations going into JPM 2024, no p...
Mayo Clinic has signed Silicon Valley tech startup Cerebras as its first generat...
